Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 5Neoplasm Metastasis 2Prostate Carcinoma Metastatic to the Bone 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Bone Metastatic Castration-resistant Prostate Cancer 1Bone Diseases 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × radium Ra 223 dichloride × Clear all
NCT02442063 2016-11-30

Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

Bayer

Phase 1 Completed
15 enrolled

Bone Diseases, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡